Mayinglong Pharmaceutical Group Co (SHSE:600993) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600993 Mayinglong Pharmaceutical Group Co Ltd SHSE:600993
86 GF Score
Price ¥22.55
GF Value ¥29.62
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Mayinglong Pharmaceutical Group Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mayinglong Pharmaceutical Group Co  (SHSE:600993) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Mayinglong Pharmaceutical Group Co Cyclically Adjusted PS Ratio Related Terms


Mayinglong Pharmaceutical Group Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Mayinglong Pharmaceutical Group Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayinglong Pharmaceutical Group Co Cyclically Adjusted PS Ratio Chart

Mayinglong Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.42 3.91 3.99 4.03 4.02

Mayinglong Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.20 3.85 4.01 3.53 3.00

SHSE:600993 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mayinglong Pharmaceutical Group Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayinglong Pharmaceutical Group Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayinglong Pharmaceutical Group Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mayinglong Pharmaceutical Group Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600993
86GF Score
Mayinglong Pharmaceutical Group Co Ltd SHSE:600993
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayinglong Pharmaceutical Group Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Mayinglong Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Mayinglong Pharmaceutical Group Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.318/116.0564*116.0564
=2.318

Current CPI (Jun. 2026) = 116.0564.

Mayinglong Pharmaceutical Group Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.063 102.400 1.205
201612 1.594 102.600 1.803
201703 0.884 103.200 0.994
201706 0.909 103.100 1.023
201709 0.936 104.100 1.044
201712 1.283 104.500 1.425
201803 1.139 105.300 1.255
201806 1.324 104.900 1.465
201809 1.196 106.600 1.302
201812 1.390 106.500 1.515
201903 1.401 107.700 1.510
201906 1.532 107.700 1.651
201909 1.493 109.800 1.578
201912 1.800 111.200 1.879
202003 0.766 112.300 0.792
202006 1.490 110.400 1.566
202009 1.737 111.700 1.805
202012 2.434 111.500 2.533
202103 1.986 112.662 2.046
202106 1.859 111.769 1.930
202109 1.985 112.215 2.053
202112 1.964 113.108 2.015
202203 2.188 114.335 2.221
202206 2.256 114.558 2.286
202209 1.975 115.339 1.987
202212 1.716 115.116 1.730
202303 1.921 115.116 1.937
202306 1.859 114.558 1.883
202309 1.853 115.339 1.865
202312 1.588 114.781 1.606
202403 2.193 115.227 2.209
202406 2.247 114.781 2.272
202409 1.990 115.785 1.995
202412 2.157 114.893 2.179
202503 2.229 115.116 2.247
202506 2.255 114.907 2.278
202509 2.045 115.471 2.055
202512 2.388 115.832 2.393
202603 2.349 116.303 2.344
202606 2.318 116.056 2.318

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?

Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥22.55 is trading 23.9% below its estimated GF Value™ of ¥29.62. GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:600993:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ¥29.62 vs. price of ¥22.55 (23.9% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mayinglong Pharmaceutical Group Co Business Description

Address No. 100 Zhoujiawan, Nanhu, Wuchang District, Wuhan, Hubei, CHN, 430064
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
86GF Score

Get the complete analysis for SHSE:600993

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥22.55
Price
¥29.62
GF Value